- Home
- BKNG vs GILD Comparison
BKNG vs GILD Comparison
Compare BKNG & GILD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | BKNG | GILD |
|---|---|---|
| Founded | 1997 | 1987 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Transportation Services | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 166.8B | 147.6B |
| IPO Year | 1999 | 1992 |
Fundamental Metrics
Financial Performance| Metric | BKNG | GILD |
|---|---|---|
| Price | $5,473.10 | $119.91 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 27 | 20 |
| Target Price | ★ $6,107.70 | $127.10 |
| AVG Volume (30 Days) | 305.4K | ★ 7.0M |
| Earning Date | 10-28-2025 | 10-30-2025 |
| Dividend Yield | 0.72% | ★ 2.62% |
| EPS Growth | 5.01 | ★ 6514.05 |
| EPS | ★ 153.22 | 6.42 |
| Revenue | $26,039,000,000.00 | ★ $29,087,000,000.00 |
| Revenue This Year | $14.53 | $3.63 |
| Revenue Next Year | $8.97 | $2.97 |
| P/E Ratio | $34.60 | ★ $18.75 |
| Revenue Growth | ★ 12.96 | 2.79 |
| 52 Week Low | $4,096.23 | $88.57 |
| 52 Week High | $5,839.41 | $128.70 |
Technical Indicators
Market Signals| Indicator | BKNG | GILD |
|---|---|---|
| Relative Strength Index (RSI) | 69.32 | 43.72 |
| Support Level | $5,002.19 | $119.53 |
| Resistance Level | $5,365.59 | $123.74 |
| Average True Range (ATR) | 132.91 | 2.58 |
| MACD | 59.66 | -0.71 |
| Stochastic Oscillator | 98.91 | 12.31 |
Price Performance
Historical ComparisonAbout BKNG Booking Holdings Inc.
Booking is the world's largest online travel agency by sales, offering booking and payment services for hotel and alternative accommodation rooms, airlines, rental cars, restaurants, cruises, experiences, and other vacation packages. The company operates several branded travel booking sites, including Booking.com, Agoda, OpenTable, Rentalcars.com, Kayak, and Momondo. Transaction fees for online bookings account for the bulk of revenue and profits.
About GILD Gilead Sciences Inc.
Gilead Sciences develops and markets therapies to treat and prevent life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of newer combination regimens that remain standards of care. Gilead is also growing its presence in the oncology market via acquisitions, led by CAR-T cell therapy Yescarta/Tecartus (from Kite) and breast and bladder cancer therapy Trodelvy (from Immunomedics).